CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus Ongoing Development On Autoimmune Indications
ITCI: 33% | Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary Endpoint
BRTX: 63% | BioRestorative Therapies shares are trading higher after the company announced FDA clearance of its Phase 2 BRTX-100 clinical study protocol amendment.